Company intelligence / Profile preview

Stop

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Stop is a pre-clinical stage biotechnology company focused on developing first-in-class therapeutics to prevent programmed cell death in acute disease states. The company's proprietary platform, STOP (Selective Targeting of Programmed Cell Death), utilizes small molecules and peptides designed to inhibit specific caspases involved in apoptosis. By targeting the executioner caspases, Stop aims to mitigate tissue damage in conditions such as acute kidney injury and myocardial infarction. Their lead programs are currently undergoing optimization and validation in various animal models of ischemia-reperfusion injury.

Therapeutic areas: CardiovascularNephrologyOther
Modalities: Small moleculePeptides
Industry: Biotech

Beyond the preview

Go deeper on Stop.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stop.

Explore the full profile